RxDoctor Payments Data

Gregory Robertson, MD

Internal Medicine · Newport Beach, CANPI 1932281011

Payments from drug & device makers

$22,981in general payments, 2019–2025

Across 947 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$3K
  • AstraZeneca$3K
  • Lilly USA, LLC$2K
  • Novo Nordisk$2K
  • AbbVie$2K
  • Pharming Healthcare, Inc.$2K
  • plus $9K from 46 others

What the payments were for

  • Travel & lodging$100%
  • Food & beverage$22,86399%
  • Education$1080%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,981 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$285,160
Medicare patients
247
Services billed
7,527

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide109$148,274
MounjaroTirzepatide125$135,096
JardianceEmpagliflozin84$110,177
EliquisApixaban72$58,852
FarxigaDapagliflozin Propanediol40$44,240
MyrbetriqMirabegron36$36,016
Repatha SureclickEvolocumab34$28,413
XareltoRivaroxaban22$27,208
VascepaIcosapent Ethyl36$19,129
Humalog Kwikpen U-200Insulin Lispro16$12,811
Testosterone49$10,562
EdarbyclorAzilsartan Med/Chlorthalidone22$9,261
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,012
BrilintaTicagrelor11$6,655
Rosuvastatin Calcium242$4,720

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,253$148,274109 claims
Lilly USA, LLCMounjaro$2,459$135,096125 claims
Boehringer IngelheimJardiance$208$110,17784 claims
PfizerEliquis$884$58,85272 claims
AstraZenecaFarxiga, Breztri Aerosphere, Brilinta$2,784$57,90662 claims
Astellas Pharma US IncMyrbetriq$578$36,01636 claims
Johnson & JohnsonXarelto$1,030$27,20822 claims
Arbor Pharmaceuticals, Inc.Edarbyclor$59$9,26122 claims
AbbVieSynthroid$2,052$4,22345 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$19$95013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Newport Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →